Yinghong Wang

The University of Texas MD Anderson Cancer Center

Also affiliated with Jinggangshan University, Hangzhou Center for Disease Control and Prevention, Jiangxi Institute of Red Soil

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 17 papers. Top paper: “Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity”.

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

Cancer Cell(2022)10.1016/j.ccell.2022.04.004

N/A

4.7DataRank · unranked

350 citations

Daniel H. Johnson, Noha Abdel‐Wahab, Wai Chin Foo, Salah-Eddine Bentebibel, May Daher +32 more

Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events

Frontiers in Immunology(2023)10.3389/fimmu.2023.1322818

N/A

0.357DataRank · unranked

6 citations

Quan‐Zhen Li, Qi Wang, Natalie I. Vokes, Ajay Sheshadri, Jianjun Gao +14 more

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-003277

N/A

0DataRank · unranked

118 citations

David M. Faleck, Anusha Shirwaikar Thomas, Jessica Harris, Deepika Satish, Xuemei Wang +13 more

A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps2676

N/A

0DataRank · unranked

29 citations

Michael Dougan, Sarthak Gupta, Laura C. Cappelli, Tamiko R. Katsumoto, Osama E. Rahma +15 more

Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment

Science Translational Medicine(2022)10.1126/scitranslmed.abo3445

N/A

0DataRank · unranked

63 citations

Diana H. Wiesnoski, Chia‐Chi Chang, Wen-Bin Tsai, Dung Pham, Saira Ahmed +54 more

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4176

N/A

0DataRank · unranked

56 citations

Robert Q. Le, Alexei Ionan, Ruo‐Jing Li, Yinghong Wang, Ramadevi Gudi +16 more

375: CONCURRENT IMMUNE CHECKPOINT INHIBITION AND SELECTIVE IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH IMMUNE-RELATED ENTEROCOLITIS

Gastroenterology(2022)10.1016/s0016-5085(22)60201-4

N/A

0DataRank · unranked

1 citations

Fangwen Zou, Sienna Durbin, Barbara E. Dutra, Donna Leet, Hamzah Abu‐Sbeih +8 more

Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases

Research Square(2022)10.21203/rs.3.rs-2372243/v1

N/A

0DataRank · unranked

1 citations

Malek Shatila, Cynthia Liu, Jianbo Wang, Mehmet Altan, Hao Chi Zhang +3 more

Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007195

N/A

0DataRank · unranked

28 citations

Fangwen Zou, Sienna Durbin, Barbara E. Dutra, Hamzah Abu‐Sbeih, Anusha Shirwaikar Thomas +11 more

Microbiome influencers of checkpoint blockade–associated toxicity

The Journal of Experimental Medicine(2023)10.1084/jem.20220948

N/A

0DataRank · unranked

34 citations

Robert R. Jenq, Jennifer A. Wargo, Stephanie S. Watowich, Yinghong Wang

Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis

Cancers(2023)10.3390/cancers15082329

N/A

0DataRank · unranked

8 citations

Malek Shatila, Guofan Xu, Yang Lu, Antony Mathew, Wasay Mohajir +5 more

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

Hepatology Communications(2023)10.1097/hc9.0000000000000302

N/A

0DataRank · unranked

11 citations

Bernhard Scheiner, Antonio D ́Alessio, Claudia Angela Maria Fulgenzi, Martin Schönlein, Lorenz Kocheise +31 more

Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer

Journal of Cancer(2023)10.7150/jca.84261

N/A

0DataRank · unranked

9 citations

Malek Shatila, Antony Mathew, Antonio Pizuorno Machado, Austin R. Thomas, Hao Chi Zhang +9 more

Toxicity in the era of immune checkpoint inhibitor therapy

Frontiers in Immunology(2024)10.3389/fimmu.2024.1447021

N/A

0DataRank · unranked

61 citations

Naimah Turner, Fernanda G. Kugeratski, Rene Rico, Jocelynn Colunga-Minutti, Rayansh Poojary +13 more

AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review

Gastroenterology(2020)10.1053/j.gastro.2020.08.063

N/A

0DataRank · unranked

272 citations

Yinghong Wang, Alberto Rubio‐Tapia, Joseph K. Lim, Michael Dougan

Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events

Journal of the National Comprehensive Cancer Network(2024)10.6004/jnccn.2023.7119

N/A

0DataRank · unranked

2 citations

Nicolas L. Palaskas, Bilal A. Siddiqui, Jennifer L. McQuade, Jamie S. Lin, Sumit K. Subudhi +8 more

A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps3158

N/A

0DataRank · unranked

6 citations

María E. Suarez‐Almazor, Jeane Painter, Tanner M. Johanns, Michael Dougan, Laura C. Cappelli +15 more